Literature DB >> 15677600

Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.

Richard S Schottenfeld1, Marek C Chawarski, Juliana R Pakes, Michael V Pantalon, Kathleen M Carroll, Thomas R Kosten.   

Abstract

OBJECTIVE: Physicians may prescribe buprenorphine for opioid agonist maintenance treatment outside of narcotic treatment programs, but treatment guidelines for patients with co-occurring cocaine and opioid dependence are not available. This study compares effects of buprenorphine and methadone and evaluates the efficacy of combining contingency management with maintenance treatment for patients with co-occurring cocaine and opioid dependence.
METHOD: Subjects with cocaine and opioid dependence (N=162) were provided manual-guided counseling and randomly assigned in a double-blind design to receive daily sublingual buprenorphine (12-16 mg) or methadone (65-85 mg p.o.) and to contingency management or performance feedback. Contingency management subjects received monetary vouchers for opioid- and cocaine-negative urine tests, which were conducted three times a week; voucher value escalated during the first 12 weeks for consecutive drug-free tests and was reduced to a nominal value in weeks 13-24. Performance feedback subjects received slips of paper indicating the urine test results. The primary outcome measures were the maximum number of consecutive weeks abstinent from illicit opioids and cocaine and the proportion of drug-free tests. Analytic models included two-by-two analysis of variance and mixed-model repeated-measures analysis of variance.
RESULTS: Methadone-treated subjects remained in treatment significantly longer and achieved significantly longer periods of sustained abstinence and a greater proportion drug-free tests, compared with subjects who received buprenorphine. Subjects receiving contingency management achieved significantly longer periods of abstinence and a greater proportion drug-free tests during the period of escalating voucher value, compared with those who received performance feedback, but there were no significant differences between groups in these variables during the entire 24-week study.
CONCLUSIONS: Methadone may be superior to buprenorphine for maintenance treatment of patients with co-occurring cocaine and opioid dependence. Combining methadone or buprenorphine with contingency management may improve treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677600     DOI: 10.1176/appi.ajp.162.2.340

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  40 in total

1.  Anticipatory reward processing among cocaine-dependent individuals with and without concurrent methadone-maintenance treatment: Relationship to treatment response.

Authors:  Sarah W Yip; Elise E DeVito; Hedy Kober; Patrick D Worhunsky; Kathleen M Carroll; Marc N Potenza
Journal:  Drug Alcohol Depend       Date:  2016-07-16       Impact factor: 4.492

Review 2.  Recent advances in the psychotherapy of addictive disorders.

Authors:  Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

3.  Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin.

Authors:  Udi E Ghitza; David H Epstein; John Schmittner; Massoud Vahabzadeh; Jia-Ling Lin; Kenzie L Preston
Journal:  J Consult Clin Psychol       Date:  2007-10

Review 4.  Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Authors:  Erik W Gunderson; David A Fiellin
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Opioid abstinence reinforcement delays heroin lapse during buprenorphine dose tapering.

Authors:  Mark K Greenwald
Journal:  J Appl Behav Anal       Date:  2008

Review 6.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

Review 7.  Drug abstinence: exploring animal models and behavioral treatment strategies.

Authors:  Joshua A Peck; Robert Ranaldi
Journal:  Psychopharmacology (Berl)       Date:  2014-03-16       Impact factor: 4.530

8.  Evaluating a longitudinal mediation model of perceived stress, depressive symptoms, and substance use treatment outcomes.

Authors:  Corey R Roos; Brian D Kiluk; R Kathryn McHugh; Kathleen M Carroll
Journal:  Psychol Addict Behav       Date:  2020-04-16

Review 9.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Authors:  Jean Bonhomme; Ruth S Shim; Richard Gooden; Dawn Tyus; George Rust
Journal:  J Natl Med Assoc       Date:  2012 Jul-Aug       Impact factor: 1.798

10.  Contingency management is efficacious in opioid-dependent outpatients not maintained on agonist pharmacotherapy.

Authors:  Nancy M Petry; Kathleen M Carroll
Journal:  Psychol Addict Behav       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.